Product Description
for the Treatment of Acne Vulgaris (Sourced from: https://clinicaltrials.gov/ct2/show/NCT01326780)
Mechanisms of Action: MCR Antagonist
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Topical
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Johnson & Johnson
Company Location: Eastern America
Company CEO: Joaquin Duato
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Acne Vulgaris
Phase 1: Acne Vulgaris|Acute Respiratory Distress Syndrome
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT01492647 |
CR018673 | P1 |
Completed |
Acne Vulgaris |
2011-10-01 |
2019-03-19 |
Treatments |
|
NCT01494714 |
CR018670 | P1 |
Completed |
Acute Respiratory Distress Syndrome |
2011-09-01 |
2019-03-19 |
Treatments |
|
NCT01326780 |
CA-P-8023 | P2 |
Completed |
Acne Vulgaris |
2012-03-31 |
2019-10-17 |
Primary Completion Date|Primary Endpoints|Start Date|Study Completion Date|Treatments |
Recent News Events
Date |
Type |
Title |
|---|